Diagnostic Accuracy of Glycogen Phosphorylase BB for Myocardial Infarction: A Systematic Review and Meta-analysis

Overview

Journal J Clin Lab Anal

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
Pathology

Date 2022 Mar 24

PMID 35325479

Authors

Anup Ghimire

Subarna Giri

Niharika Khanal

Shivani Rayamajhi

Anjila Thapa

Anil Bist

Surya Devkota

Affiliations

Soon will be listed here.

Abstract

Purpose: We tried to investigate the diagnostic accuracy of glycogen phosphorylase BB as a cardiac marker for myocardial infarction.

Methods: We searched through different electronic databases (PubMed, Google-scholar, Embase, and Cochrane Library) to locate relevant articles. Studies, with sufficient data to reconstruct a 2 × 2 contingency table, met our inclusion criteria were included. Three reviewers independently screened the articles. Discrepancies were resolved by other reviewers. Unpublished data were requested from the authors of the study via email. Subsequently, data extraction was done using a standardized form and quality assessment of studies using the QUADAS-2 tool. Meta-analysis was done using a bivariate model using R software.

Results: Fourteen studies were selected for the final evaluation, which yielded the summary points: pooled sensitivity 87.77% (77.52%-93.72%, I = 86%), pooled specificity 88.45% (75.59%-94.99%, I = 88%), pooled DOR 49.37(14.53-167.72, I = 89%), and AUC of SROC was 0.923. The lambda value of the HSROC curve was 3.670. The Fagan plot showed that GPBB increases the pretest probability of myocardial infarction from 46% to 81% when positive, and it lowers the same probability to 12% when negative.

Conclusion: With these results, we can conclude that GPBB has modest accuracy in screening myocardial infarction, but the limitations of the study warrant further high-quality studies to confirm its usefulness in predicting myocardial infarction (MI).

Citing Articles

Brain-Type Glycogen Phosphorylase (PYGB) in the Pathologies of Diseases: A Systematic Review.

Yang C, Wang H, Shao M, Chu F, He Y, Chen X Cells. 2024; 13(3.

PMID: 38334681 PMC: 10854662. DOI: 10.3390/cells13030289.

Diagnostic accuracy of glycogen phosphorylase BB for myocardial infarction: A systematic review and meta-analysis.

Ghimire A, Giri S, Khanal N, Rayamajhi S, Thapa A, Bist A J Clin Lab Anal. 2022; 36(5):e24368.

PMID: 35325479 PMC: 9102511. DOI: 10.1002/jcla.24368.

References

Meune C, Wahbi K, Weber S, Zuily S, Cynober L, Chenevier-Gobeaux C . Performance of glycogen phosphorylase isoenzyme BB is weak in the detection of patients with non-ST-elevation acute coronary syndrome. Clin Biochem. 2011; 44(16):1343-5. DOI: 10.1016/j.clinbiochem.2011.07.008. View

Stejskal D, Lacnak B, Jedelsky L, Stepanova L, Proskova J, Solichova P . Use of glycogen phosphorylase BB measurement with POCT in the diagnosis of acute coronary syndromes. A comparison with the ELISA method. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008; 151(2):247-9. DOI: 10.5507/bp.2007.041. View

Whiting P, Rutjes A, Westwood M, Mallett S, Deeks J, Reitsma J . QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155(8):529-36. DOI: 10.7326/0003-4819-155-8-201110180-00009. View

Dai H, Much A, Maor E, Asher E, Younis A, Xu Y . Global, regional, and national burden of ischaemic heart disease and its attributable risk factors, 1990-2017: results from the Global Burden of Disease Study 2017. Eur Heart J Qual Care Clin Outcomes. 2020; 8(1):50-60. PMC: 8728029. DOI: 10.1093/ehjqcco/qcaa076. View

Shortt C, Worster A, Hill S, Kavsak P . Comparison of hs-cTnI, hs-cTnT, hFABP and GPBB for identifying early adverse cardiac events in patients presenting within six hours of chest pain-onset. Clin Chim Acta. 2013; 419:39-41. DOI: 10.1016/j.cca.2013.01.008. View

Balotin N . Myocardial infarction, its diagnosis and treatment; literature review. Dis Chest. 1959; 36(1):86-94. View

Braunwald E, Antman E, Beasley J, Califf R, Cheitlin M, Hochman J . ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on.... Circulation. 2000; 102(10):1193-209. DOI: 10.1161/01.cir.102.10.1193. View

Reitsma J, Glas A, Rutjes A, Scholten R, Bossuyt P, Zwinderman A . Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol. 2005; 58(10):982-90. DOI: 10.1016/j.jclinepi.2005.02.022. View

Apple F . A new season for cardiac troponin assays: it's time to keep a scorecard. Clin Chem. 2009; 55(7):1303-6. DOI: 10.1373/clinchem.2009.128363. View

10.

Meyer F, Heilmeyer Jr L, Haschke R, FISCHER E . Control of phosphorylase activity in a muscle glycogen particle. I. Isolation and characterization of the protein-glycogen complex. J Biol Chem. 1970; 245(24):6642-8. View

11.

Jacob R, Khan M . Cardiac Biomarkers: What Is and What Can Be. Indian J Cardiovasc Dis Women WINCARS. 2020; 3(4):240-244. PMC: 6957084. DOI: 10.1055/s-0039-1679104. View

12.

McCann C, Glover B, Menown I, Moore M, McEneny J, Owens C . Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T. Eur Heart J. 2008; 29(23):2843-50. DOI: 10.1093/eurheartj/ehn363. View

13.

Aydin S, Ugur K, Aydin S, Sahin I, Yardim M . Biomarkers in acute myocardial infarction: current perspectives. Vasc Health Risk Manag. 2019; 15:1-10. PMC: 6340361. DOI: 10.2147/VHRM.S166157. View

14.

Lackner K . Laboratory diagnostics of myocardial infarction--troponins and beyond. Clin Chem Lab Med. 2012; 51(1):83-9. DOI: 10.1515/cclm-2012-0572. View

15.

Li W, Chen X, Nie X, Lin X, Cheng Y, Hu C . Early diagnostic and prognostic utility of high-sensitive troponin assays in acute myocardial infarction: a meta-analysis. Intern Med J. 2014; 45(7):748-56. DOI: 10.1111/imj.12642. View

16.

Mion M, Novello E, Altinier S, Rocco S, Zaninotto M, Plebani M . Analytical and clinical performance of a fully automated cardiac multi-markers strategy based on protein biochip microarray technology. Clin Biochem. 2007; 40(16-17):1245-51. DOI: 10.1016/j.clinbiochem.2007.07.018. View

17.

Deeks J, Macaskill P, Irwig L . The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005; 58(9):882-93. DOI: 10.1016/j.jclinepi.2005.01.016. View

18.

Figiel L, Wraga M, Bednarkiewicz Z, Lipiec P, Smigielski J, Krzeminska-Pakula M . Direct comparison of the diagnostic value of point-of-care tests detecting heart-type fatty acid binding protein or glycogen phosphorylase isoenzyme BB in patients with acute coronary syndromes with persistent ST-segment elevation. Kardiol Pol. 2011; 69(1):1-6. View

19.

Bozkurt S, Kaya E, Okutucu S, Aytemir K, Coskun F, Oto A . The diagnostic and prognostic value of first hour glycogen phosphorylase isoenzyme BB level in acute coronary syndrome. Cardiol J. 2011; 18(5):496-502. DOI: 10.5603/cj.2011.0004. View

20.

Ghimire A, Giri S, Khanal N, Rayamajhi S, Thapa A, Bist A . Diagnostic accuracy of glycogen phosphorylase BB for myocardial infarction: A systematic review and meta-analysis. J Clin Lab Anal. 2022; 36(5):e24368. PMC: 9102511. DOI: 10.1002/jcla.24368. View